Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023
18 3월 2024 - 11:00PM
Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”),
(NYSE American: CHRO), a pioneer in the development of non-opioid
pain treatment therapeutics, today announced that its interim CEO
Frank Knuettel, has been appointed as the Company’s permanent CEO.
“I’m grateful to our board of directors and
Chromocell’s investors for their support over the past seven months
and for the confidence they have shown in my ability to lead the
Company,” said Frank Knuettel, CEO of Chromocell. “I look forward
to continuing to work with them and leading the effort to push
forward our announced clinical and pre-clinical programs and
developing additional programs based on our proprietary non-opioid
pain therapy compound.”
”Since being appointed Interim CEO, Frank has
established himself as a goal-oriented and pragmatic leader,” added
Todd Davis, Chairman of the Board of Directors for the Company.
“The Board is pleased to remove the “interim” title and believes
Frank has the experience, knowledge, and strategic perspective to
build our current programs, expand our portfolio of non-opioid pain
treatment therapies, and seek suitable monetization of certain
programs at the appropriate times.”
Mr. Knuettel was previously appointed Interim
CEO in July 2023, while currently serving as the Company’s CFO, a
role he will continue to fill for the near future.
About Chromocell Therapeutics
Corp.
Chromocell Therapeutics Corporation is a
clinical-stage biotechnology company focused on developing and
commercializing novel, non-opioid, non-addictive, therapeutics to
alleviate pain and other associated medical conditions. The
Company’s initial clinical focus is to selectively target the
sodium ion-channel known as NaV1.7 for the treatment of various
types of chronic neuropathic pain and eye pain. The Company’s
portfolio also includes pre-clinical work on other sodium channel
receptor subtypes and the Company intends to explore these and
other compounds for the treatment of additional pain indications.
For company updates and to learn more about Chromocell,
visit www.chromocell.com or follow us on social
media.
Forward-Looking Statements
This press release contains forward-looking
statements regarding the Company’s current expectations. These
forward-looking statements include, without limitation, references
to the Company’s expectations regarding the closing of the public
offering and its anticipated use of net proceeds from the offering.
These statements are not guarantees of future performance and are
subject to certain risks, uncertainties and assumptions that are
difficult to predict. Factors that could cause actual results to
differ include, but are not limited to, risks and uncertainties
related to the satisfaction of customary closing conditions related
to the public offering, or factors that result in changes to the
Company’s anticipated use of proceeds. These and other risks and
uncertainties are described more fully in the section captioned
“Risk Factors” in the Company’s Registration Statement on Form S-1
related to the public offering (SEC File No. 333-269188).
Forward-looking statements contained in this announcement are made
as of this date, and the Company undertakes no duty to update such
information except as required under applicable law.
Chromocell Media and Investor Inquires:
LR Advisors LLC.Jason
Assad678-570-6791Jason@Chromocell.com
Chromocell Therapeutics (AMEX:CHRO)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Chromocell Therapeutics (AMEX:CHRO)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024